QSAR models for P450 (2D6) substrate activity

References

• Vermeulen , NPE . 2003 . Prediction of drug metabolism: the case of cytochrome P450 2D6 . Curr. Top. Med. Chem. , 3 : 1227 – 1239 .
   PubMed Web of Science ®Google Scholar
• Zanger , UM , Raimundo , S and Eichelbaum , M . 2004 . Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry . Naunyn–Schmiedeberg's Arch. Pharmacol. , 369 : 23 – 37 .
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg , M . 2005 . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity . Pharmacogenomics J. , 5 : 6 – 13 .
   PubMed Web of Science ®Google Scholar
• Lindup , WE and Kitteringham , NR . 2005 . “ Cytochrome P450 Example ” . In Enzymes and Their Inhibition: Drug Development , Edited by: Smith , HJ and Simons , C . Boca Raton, FL : CRC Press . Chapter 2
   Google Scholar
• Poolsup , N , Po , ALW and Knight , TL . 2000 . Pharmacogenetics and psychopharmacotherapy . J. Clin. Pharm. Ther. , 25 : 197 – 220 .
   PubMed Web of Science ®Google Scholar
• Testa , B and Soine , W . 2003 . “ Principles of drug Metabolism ” . In Burger's Medicinal Chemistry and Drug Discovery, , 6th , Edited by: Abraham , DJ . 431 – 498 . Hoboken, NJ : John Wiley & Sons .
   Google Scholar
• Ingelman-Sundberg , M , Daly , AK and Nebert , DW . CYP2D6 allele nomenclature , Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee, Accessed 3 March 2008, Available at http://www.cypalleles.ki.se/
   Google Scholar
• Cascorbi , I . 2006 . Genetic basis of toxic reactions to drugs and chemicals . Toxicol. Lett. , 162 : 16 – 28 .
   PubMed Web of Science ®Google Scholar
• Bertilsson , L , Dahl , ML , Dalen , P and Al-Shurbaji , A . 2002 . Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs . Br. J. Clin. Pharmacol. , 53 : 111 – 122 .
   PubMed Web of Science ®Google Scholar
• Brown , TP , Rumsby , PC , Capleton , AC , Rushton , L and Levy , LS . 2006 . Pesticides and Parkinson's disease—Is there a link? . Environ. Health Perspect. , 114 : 156 – 164 .
   PubMed Web of Science ®Google Scholar
• Elbaz , A , Levecque , C , Clavel , J , Vidal , JS , Richard , F , Amouyel , P , Alperovitch , A , Chartier-Harlin , MC and Tzourio , C . 2004 . CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease . Ann. Neurol. , 55 : 430 – 434 .
   PubMed Web of Science ®Google Scholar
• Elbaz , A , Dufouil , C and Alperovitch , A . 2007 . Interaction between genes and environment in neurodegenerative diseases . C. R. Biol. , 330 : 318 – 328 .
   PubMed Web of Science ®Google Scholar
• Livingstone , DJ . 2004 . “ Building QSAR models: a practical guide ” . In Predicting Chemical Toxicity and Fate , Edited by: Cronin , MTD and Livingstone , DJ . Boca Raton, FL : CRC Press . Chapter 7
   Google Scholar
• Walker , JD and Schultz , TW . 2003 . “ Structure activity relationships for predicting ecological effects of chemicals ” . In Handbook of Ecotoxicology,, , 2nd , Edited by: Hoffman , DJ , Rattner , BA , Burton , GA Jr and Cairns , J Jr . Boca Raton, FL : CRC Press . Chapter 33
   Google Scholar
• Klopman , G , Ivanov , J , Saiakhov , R and Chakravarti , S . 2005 . “ MC4PC––An artificial intelligence approach to the discovery of quantitative structure-toxic activity relationships ” . In Predictive Toxicology , Edited by: Helma , C . 423 – 457 . New York : Taylor & Francis .
   Google Scholar
• Roberts , G , Myatt , GJ , Johnson , WP , Cross , KP and Blower , PE . 2000 . LeadScope: software for exploring large sets of screening data . J. Chem. Inf. Comput. Sci. , 40 : 1302 – 1314 .
   PubMedGoogle Scholar
• Yang , CH , Cross , K , Myatt , GJ , Blower , PE and Rathman , JF . 2004 . Building predictive models for protein tyrosine phosphatase 1B inhibitors based on discriminating structural features by reassembling medicinal chemistry building blocks . J. Med. Chem. , 47 : 5984 – 5994 .
   PubMed Web of Science ®Google Scholar
• Hall , LH and Kier , LB . 1995 . Electrotopological state indexes for atom types––a novel combination of electronic, topological, and valence state information . J. Chem. Inf. Comput. Sci. , 35 : 1039 – 1045 .
   Google Scholar
• Kellogg , GE , Kier , LB , Gaillard , P and Hall , LH . 1996 . E-state fields: Applications to 3D QSAR . J. Comput. Aided Mol. Des. , 10 : 513 – 520 .
   PubMed Web of Science ®Google Scholar
• Hall , LH and Hall , LM . 2005 . QSAR modeling based on structure-information for properties of interest in human health . SAR QSAR Environ. Res. , 16 : 13 – 41 .
   PubMed Web of Science ®Google Scholar
• Hall , LH . 2004 . A structure-information approach to the prediction of biological activities and properties . Chem. Biodivers. , 1 : 183 – 201 .
   PubMed Web of Science ®Google Scholar
• Hall , LH and Kier , LB . 2001 . Issues in representation of molecular structure––the development of molecular connectivity . J. Mol. Graphics Modell. , 20 : 4 – 18 .
   Google Scholar
• Yap , CW and Chen , YZ . 2005 . Prediction of cytochrome p450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines . J. Chem. Inf. Model. , 45 : 982 – 992 .
   PubMed Web of Science ®Google Scholar
• Peters , FT , Dragan , CA , Wilde , DR , Meyer , MR , Zapp , J , Bureik , M and Maurer , HH . 2007 . Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4′-hydroxymethyl-alpha-pyrrolidinobutyrophenone . Biochem. Pharmacol. , 74 : 511 – 520 .
   PubMed Web of Science ®Google Scholar
• Hodgson , E . 2001 . In vitro human phase I metabolism of xenobiotics I: Pesticides and related chemicals used in agriculture and public health, September 2001 . J. Biochem. Mol. Toxicol. , 15 : 296 – 299 .
   PubMed Web of Science ®Google Scholar
• Rendic , S . 2002 . Summary of information on human CYP enzymes: Human P450 metabolism data . Drug Metab. Rev. , 34 : 83 – 448 .
   PubMed Web of Science ®Google Scholar
• Skerjanec , A . 2006 . The clinical pharmacokinetics of darifenacin . Clin. Pharmacokinet. , 45 : 325 – 350 .
   PubMed Web of Science ®Google Scholar
• Skinner , MH , Kuan , HY , Pan , A , Sathirakul , K , Knadler , MP , Gonzales , CR , Yeo , KP , Reddy , S , Lim , M , Ayan-Oshodi , M and Wise , SD . 2003 . Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers . Clin Pharmacol Ther. , 73 : 170 – 177 .
   PubMed Web of Science ®Google Scholar
• Urichuk , L , Prior , TI , Dursun , S and Baker , G . 2008 . Metabolism of atypical antipsychotics: Involvement of cytochrome P450 enzymes and relevance for drug-drug interactions . Curr. Drug Metab. , 9 : 410 – 418 .
   PubMed Web of Science ®Google Scholar
• Koumis , T and Samuel , S . 2005 . Tiotropium bromide: A new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease . Clin. Ther. , 27 : 377 – 392 .
   PubMed Web of Science ®Google Scholar
• Dong , BJ . 2005 . Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism . Clin. Ther. , 27 : 1725 – 1751 .
   PubMed Web of Science ®Google Scholar
• Draper , E . New drug bulletin: Budesonide and Formoterol (Symbicort-AstraZeneca) , Edited by: Fox , E . University of Utah Hospitals and Clinics . Accessed 12 February 2009, Available at http://healthcare.utah.edu/pharmacy/bulletins/NDB_136.pdf
   Google Scholar
• Friedl , H and Stampfer , E . 2002 . “ Cross-validation ” . In Encyclopedia of Environmetrics , Edited by: El-Shaarawi , AH and Piegorsch , WW . 452 – 460 . Chichester : John Wiley and Sons .
   Google Scholar
• Cooper , JA , Saracci , R and Cole , P . 1979 . Describing the validity of carcinogen screening-tests . Br. J. Cancer , 39 : 87 – 89 .
   PubMed Web of Science ®Google Scholar
• de Groot , MJ , Ackland , MJ , Horne , VA , Alex , AA and Jones , BC . 1999 . A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6 . J. Med. Chem. , 42 : 4062 – 4070 .
   PubMed Web of Science ®Google Scholar
• Wolff , T , Distlerath , LM , Worthington , MT , Groopman , JD , Hammons , GJ , Kadlubar , FF , Prough , RA , Martin , MV and Guengerich , FP . 1985 . Substrate-specificity of human-liver cytochrome-P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling . Cancer Res. , 45 : 2116 – 2122 .
   PubMed Web of Science ®Google Scholar
• Meyer , UA , Gut , J , Kronbach , T , Skoda , C , Meier , UT , Catin , T and Dayer , P . 1986 . The molecular mechanisms of 2 common polymorphisms of drug oxidation––evidence for functional-changes in cytochrome-P-450 isozymes catalyzing bufuralol and mephenytoin oxidation . Xenobiotica , 16 : 449 – 464 .
   PubMed Web of Science ®Google Scholar
• Islam , SA , Wolf , CR , Lennard , MS and Sternberg , MJE . 1991 . A 3-Dimensional molecular template for substrates of human cytochrome-P450 involved in debrisoquine 4-hydroxylation . Carcinogenesis , 12 : 2211 – 2219 .
   PubMed Web of Science ®Google Scholar
• Koymans , L , Vermeulen , NPE , Vanacker , SABE , Tekoppele , JM , Heykants , JJP , Lavrijsen , K , Meuldermans , W and Denkelder , GMD . 1992 . A predictive model for substrates of cytochrome P450-debrisoquine (2d6) . Chem. Res. Toxicol. , 5 : 211 – 219 .
   PubMed Web of Science ®Google Scholar
• de Groot , MJ and Ekins , S . 2002 . Pharmacophore modeling of cytochromes P450 . Adv. Drug Deliv. Rev. , 54 : 367 – 383 .
   PubMed Web of Science ®Google Scholar
• Rowland , P , Blaney , FE , Smyth , MG , Jones , JJ , Leydon , VR , Oxbrow , AK , Lewis , CJ , Tennant , MG , Modi , S , Eggleston , DS , Chenery , RJ and Bridges , AM . 2006 . Crystal structure of human cytochrome P450 2D6 . J. Biol. Chem. , 281 : 7614 – 7622 .
   PubMed Web of Science ®Google Scholar
• Chohan , KK , Paine , SW and Waters , NJ . 2006 . Quantitative structure activity relationships in drug metabolism . Curr. Top. Med. Chem. , 6 : 1569 – 1578 .
   PubMed Web of Science ®Google Scholar
• Long , A and Walker , JD . 2003 . Quantitative structure–activity relationships for predicting metabolism and modeling cytochrome P450 enzyme activities . Environ. Toxicol. Chem. , 22 : 1894 – 1899 .
   PubMed Web of Science ®Google Scholar
• Ekins , S , De Groot , MJ and Jones , JP . 2001 . Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites . Drug Metab. Dispos. , 29 : 936 – 944 .
   PubMed Web of Science ®Google Scholar
• Arimoto , R . 2006 . Computational models for predicting interactions with cytochrome p450 enzyme . Curr. Top. Med. Chem. , 6 : 1609 – 1618 .
   PubMed Web of Science ®Google Scholar
• Matthews , EJ , Kruhlak , NL , Benz , RD , Contrera , JF , Marchant , CA and Yang , C . 2008 . Combined use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for windows software to achieve high-performance, high-confidence, mode of action-based predictions of chemical carcinogenesis in rodents . Toxicol. Mech. Methods , 18 : 189 – 206 .
   PubMed Web of Science ®Google Scholar
• Contrera , JF , Kruhlak , NL , Matthews , EJ and Benz , RD . 2007 . Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models . Regul. Toxicol. Pharm. , 49 : 172 – 182 .
   PubMed Web of Science ®Google Scholar